Put another way, a decline in TREM2's contribution to the innate immune response, in part driving amyloid-clearance deficits and progressive degeneration characteristic of the AD process, suggest novel therapeutic targets and treatment strategies directed at maintaining natural and homeostatic TREM2 functions. This evidence concerns the gene TREM2 and Alzheimer disease.